Updates are available Correction dated 2024-02-10
Click to view Correction: https://doi.org/10.1007/s10461-024-04265-7
-
Authors
Dunlap, Laura J.
Orme, Stephen http://orcid.org/0000-0003-3641-5745
Zarkin, Gary A.
Holtgrave, David R.
Maulsby, Catherine
Rodewald, Andrew M.
Holtyn, August F.
Silverman, Kenneth
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01AI117065)
National Institute on Drug Abuse (T32DA07209)
- License Information
-
More Information
Article History
Accepted: 13 August 2021
First Online: 26 August 2021
Change Date: 10 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10461-024-04265-7
Declarations
:
: The authors declare that they have no conflict of interest.
: The Johns Hopkins Medicine Institutional Review Board approved the study. The study was monitored by a Scientific Advisory Committee. Staff members reported all events that might be considered adverse events, including deaths, and the investigators determined if any events met the definitions of adverse events as defined by the Johns Hopkins Medicine Institutional Review Board. The investigators, the Scientific Advisory Committee and the Johns. Hopkins Medicine Institutional Review Board reviewed all adverse events annually. The study team registered the trial on Clinicialtrials.gov before recruitment began (NCT02363387).
